Bolt Biotherapeutics (BOLT) COO swaps options for lower strike price

Q: What insider transaction did Bolt Biotherapeutics (BOLT) report for its COO?

The company reported that its Chief Operating Officer cancelled several existing employee stock options with higher exercise prices and received new options with the same share amounts and expirations but a lower $5.44 exercise price , all dated 12/12/2025.

Q: What is the reporting person’s role at Bolt Biotherapeutics (BOLT)?

The reporting person is identified as an Officer of Bolt Biotherapeutics, specifically serving as the company’s Chief Operating Officer .

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Bolt Biotherapeutics, Inc. reported that its Chief Operating Officer adjusted multiple employee stock options on 12/12/2025. Existing options with higher exercise prices were cancelled, and new employee stock options with a $5.44 exercise price and the same share amounts and expiration dates were granted in exchange.

One of the new options is fully vested and exercisable. Several other new options vest in equal 1/36th installments each month after specified dates in 2023, 2024 and 2025, for so long as the reporting person continuously provides services to the company.

Insider Trade Summary

24 transactions reported

Mixed 24 txns

Insider Yonehiro Grant

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	3,214	$0.00	--
Disposition	Employee Stock Option (Right to Buy)	3,214	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	660	$0.00	--
Disposition	Employee Stock Option (Right to Buy)	660	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	822	$0.00	--
Disposition	Employee Stock Option (Right to Buy)	822	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	1,653	$0.00	--
Disposition	Employee Stock Option (Right to Buy)	1,653	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	4,642	$0.00	--
Disposition	Employee Stock Option (Right to Buy)	4,642	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	2,142	$0.00	--
Disposition	Employee Stock Option (Right to Buy)	2,142	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	4,999	$0.00	--
Disposition	Employee Stock Option (Right to Buy)	4,999	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	9,499	$0.00	--
Disposition	Employee Stock Option (Right to Buy)	9,499	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	11,399	$0.00	--
Disposition	Employee Stock Option (Right to Buy)	11,399	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	11,749	$0.00	--
Disposition	Employee Stock Option (Right to Buy)	11,749	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	7,749	$0.00	--
Disposition	Employee Stock Option (Right to Buy)	7,749	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	17,499	$0.00	--
Disposition	Employee Stock Option (Right to Buy)	17,499	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 3,214 shares (Direct)

Footnotes (1)

The option is fully vested and exercisable. The reporting person agreed to cancellation of an option granted on January 18, 2017, in exchange for a new option having a lower price. The reporting person agree to cancellation of an option granted on January 17, 2018, in exchange for a new option having a lower exercise price. The reporting person agreed to cancellation of an option granted on April 4, 2018, in exchange for a new option having a lower exercise price. The reporting person agreed to cancellation of an option granted on January 11, 2019, in exchange for a new option having a lower exercise price. The reporting person agreed to cancellation of an option granted on November 13, 2019, in exchange for a new option having a lower exercise price. The reporting person agreed to cancellation of an option granted on September 3, 2020, in exchange for a new option having a lower exercise price. The reporting person agreed to cancellation of an option granted on February 4, 2021, in exchange for a new option having a lower exercise price. The reporting person agreed to cancellation of an option granted on February 18, 2022, in exchange for a new option having a lower exercise price. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2023. The reporting person agreed to cancellation of an option granted on February 27, 2023, in exchange for a new option having a lower exercise price. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024. The reporting person agreed to cancellation of an option granted on March 4, 2024, in exchange for a new option having a lower exercise price. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024. The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2025. The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price.

Form 4 Insider Transactions: What Each Field Means →

12/16/2025 - 05:11 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yonehiro Grant

(Last)

(First)

(Middle)

C/O BOLT BIOTHERAPEUTICS, INC.

900 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY

94063

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		3,214		⁽¹⁾	01/17/2027	Common Stock	3,214	⁽²⁾	3,214	D
Employee Stock Option (Right to Buy)	$42	12/12/2025		D			3,214	⁽¹⁾	01/17/2027	Common Stock	3,214	⁽²⁾	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		660		⁽¹⁾	01/16/2028	Common Stock	660	⁽³⁾	660	D
Employee Stock Option (Right to Buy)	$40.6	12/12/2025		D			660	⁽¹⁾	01/17/2028	Common Stock	660	⁽³⁾	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		822		⁽¹⁾	04/03/2028	Common Stock	822	⁽⁴⁾	822	D
Employee Stock Option (Right to Buy)	$40.6	12/12/2025		D			822	⁽¹⁾	04/03/2028	Common Stock	822	⁽⁴⁾	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		1,653		⁽¹⁾	01/10/2029	Common Stock	1,653	⁽⁵⁾	1,653	D
Employee Stock Option (Right to Buy)	$44.8	12/12/2025		D			1,653	⁽¹⁾	01/10/2029	Common Stock	1,653	⁽⁵⁾	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		4,642		⁽¹⁾	11/12/2029	Common Stock	4,642	⁽⁶⁾	4,642	D
Employee Stock Option (Right to Buy)	$54.6	12/12/2025		D			4,642	⁽¹⁾	11/12/2029	Common Stock	4,642	⁽⁶⁾	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		2,142		⁽¹⁾	09/02/2030	Common Stock	2,142	⁽⁷⁾	2,142	D
Employee Stock Option (Right to Buy)	$86.8	12/12/2025		D			2,142	⁽¹⁾	09/02/2030	Common Stock	2,142	⁽⁷⁾	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		4,999		⁽¹⁾	02/03/2031	Common Stock	4,999	⁽⁸⁾	4,999	D
Employee Stock Option (Right to Buy)	$400	12/12/2025		D			4,999	⁽¹⁾	02/03/2031	Common Stock	4,999	⁽⁸⁾	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		9,499		⁽¹⁾	02/17/2032	Common Stock	9,499	⁽⁹⁾	9,499	D
Employee Stock Option (Right to Buy)	$61.6	12/12/2025		D			9,499	⁽¹⁾	02/17/2032	Common Stock	9,499	⁽⁹⁾	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		11,399		⁽¹⁰⁾	02/26/2033	Common Stock	11,399	⁽¹¹⁾	11,399	D
Employee Stock Option (Right to Buy)	$31.8	12/12/2025		D			11,399	⁽¹⁰⁾	02/26/2033	Common Stock	11,399	⁽¹¹⁾	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		11,749		⁽¹²⁾	03/03/2034	Common Stock	11,749	⁽¹³⁾	11,749	D
Employee Stock Option (Right to Buy)	$25.4	12/12/2025		D			11,749	⁽¹²⁾	03/03/2034	Common Stock	11,749	⁽¹³⁾	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		7,749		⁽¹⁴⁾	07/22/2034	Common Stock	7,749	⁽¹⁵⁾	7,749	D
Employee Stock Option (Right to Buy)	$14.602	12/12/2025		D			7,749	⁽¹⁴⁾	07/22/2034	Common Stock	7,749	⁽¹⁵⁾	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		17,499		⁽¹⁶⁾	04/30/2035	Common Stock	17,499	⁽¹⁷⁾	17,499	D
Employee Stock Option (Right to Buy)	$7.02	12/12/2025		D			17,499	⁽¹⁶⁾	04/30/2035	Common Stock	17,499	⁽¹⁷⁾	0	D

Explanation of Responses:

1. The option is fully vested and exercisable.

2. The reporting person agreed to cancellation of an option granted on January 18, 2017, in exchange for a new option having a lower price.

3. The reporting person agree to cancellation of an option granted on January 17, 2018, in exchange for a new option having a lower exercise price.

4. The reporting person agreed to cancellation of an option granted on April 4, 2018, in exchange for a new option having a lower exercise price.

5. The reporting person agreed to cancellation of an option granted on January 11, 2019, in exchange for a new option having a lower exercise price.

6. The reporting person agreed to cancellation of an option granted on November 13, 2019, in exchange for a new option having a lower exercise price.

7. The reporting person agreed to cancellation of an option granted on September 3, 2020, in exchange for a new option having a lower exercise price.

8. The reporting person agreed to cancellation of an option granted on February 4, 2021, in exchange for a new option having a lower exercise price.

9. The reporting person agreed to cancellation of an option granted on February 18, 2022, in exchange for a new option having a lower exercise price.

10. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2023.

11. The reporting person agreed to cancellation of an option granted on February 27, 2023, in exchange for a new option having a lower exercise price.

12. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024.

13. The reporting person agreed to cancellation of an option granted on March 4, 2024, in exchange for a new option having a lower exercise price.

14. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024.

15. The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price.

16. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2025.

17. The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price.

	/s/ William P. Quinn, Attorney-in-Fact	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Bolt Biotherapeutics (BOLT) report for its COO?

The company reported that its Chief Operating Officer cancelled several existing employee stock options with higher exercise prices and received new options with the same share amounts and expirations but a lower $5.44 exercise price, all dated 12/12/2025.

When did the reported Bolt Biotherapeutics COO option transactions occur?

The option cancellations and new grants for the Bolt Biotherapeutics Chief Operating Officer occurred on 12/12/2025, as shown in Table II of the filing.

What is the exercise price of the new Bolt Biotherapeutics COO stock options?

The new employee stock options granted to the Bolt Biotherapeutics Chief Operating Officer have an exercise price of $5.44 per share, replacing options that had higher exercise prices such as $42, $40.6, $44.8, and others.

Were existing Bolt Biotherapeutics options cancelled in exchange for new ones?

Yes. The explanations state that the reporting person agreed to cancellation of prior options granted between 2017 and 2025 in exchange for new options having a lower exercise price for each corresponding grant.

How do the new Bolt Biotherapeutics COO options vest?

For several grants, the filing explains that, so long as the reporting person continuously provides services, 1/36th of the shares vest each month after specified dates in 2023, 2024, and 2025. One option is reported as fully vested and exercisable.

What is the reporting person’s role at Bolt Biotherapeutics (BOLT)?

The reporting person is identified as an Officer of Bolt Biotherapeutics, specifically serving as the company’s Chief Operating Officer.